This Biotech CEO is Working on Making The Impossible Possible & Helping Us Fight Bad Bacteria.

Meet Dr. Deborah Birx (Armata Pharmaceuticals -ARMP)

Guest

CEO Full Name:

Dr. Deborah Birx CEO, Armata Pharmaceuticals

Company Name:

Armata Pharmaceuticals, Inc.

Website:

http://www.armatapharma.com/

Ticker:

$ARMP (NYSE American)

Dr. Deborah Birx Bio:

Deborah L. Birx, M.D., was appointed Chief Executive Officer on July 10, 2023. Prior to joining Armata, Dr. Birx served as a member of Innoviva's Board of Directors from March 2021 until July 2023.Dr. Birx is a world-renowned medical expert and leader who most recently served as the response coordinator of the White House Coronavirus Task Force. Previously, she served as Ambassador-at-Large, when she assumed the role of the Coordinator of the United States Government Activities to Combat HIV/AIDS and U.S. Special Representative for Global Health Diplomacy. Dr. Birx also served as the U.S. Global AIDS Coordinator where she oversaw the President's Emergency Plan for AIDS Relief (PEPFAR) at the CDC and as the Director of the U.S. Military HIV Research Program (USMHRP) at the Walter Reed Army Institute of Research.

From 1980 until 2008, Dr. Birx served in the United States Army, retiring with the rank of colonel. Dr. Birx has published over 230 manuscripts in peer-reviewed journals, authored nearly a dozen chapters in scientific publications, as well as developed and patented vaccines. She received her medical degree from the Hershey School of Medicine, Pennsylvania State University, and beginning in 1980, she trained in internal medicine and basic and clinical immunology at the Walter Reed Army Medical Center and the National Institutes of Health. Dr. Birx is board certified in internal medicine, allergy and immunology, and diagnostic and clinical laboratory immunology.

Company Bio:

Armata is a late clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization